ArticleJournal of pharmaceutical analysis2025

Synergistic approach to combating triple-negative breast cancer: DDR1-targeted antibody-drug conjugate combined with pembrolizumab.

Shoubing Zhou et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.